Treating primary HIV infection — is your HAART in it?
Don E. Smith A B and Derek J. Chan A
+ Author Affiliations
- Author Affiliations
A Albion Street Centre, South Eastern Sydney Area Health Service, NSW 2010, Australia.
B Author for correspondence; email: smithdo@sesahs.gov.nsw.au
Sexual Health 1(3) 131-135 https://doi.org/10.1071/SH04017
Submitted: 4 June 2004 Accepted: 10 August 2004 Published: 23 September 2004
References
[1] Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society — USA Panel. JAMA 2002; 288(2): 222–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[2] Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122(8): 573–9.
| PubMed |
[3] Vanhems P, Lambert J, Cooper DA, Perrin L, Carr A, Hirschel B, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998; 26(2): 323–9.
| PubMed |
[4] Vanhems P, Hirschel B, Phillips AN, Cooper DA, Vizzard J, Brassard J, et al. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis 2000; 182(1): 334–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[5] Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollock SM, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14(3): 249–58.
| PubMed |
[6] Vanhems P, Dassa C, Lambert J, Cooper DA, Perrin L, Vizzard J, et al. Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21(2): 99–106.
| PubMed |
[7] Gloster SE, Newton P, Cornforth D, Lifson JD, Williams I, Shaw GM, et al. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004; 18(5): 749–55.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[8] Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339(1): 33–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[9] Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis Lancet 2000; 355(9210): 1131–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[10] Farzadegan H, Henrard DR, Kleeberger CA, Schrager L, Kirby AJ, Saah AJ, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(5): 448–55.
| PubMed |
[11] Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9(3): 305–10.
| PubMed |
[12] Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7(1): 51–7.
| PubMed |
[13] Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181(3): 872–80.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[14] Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272(5265): 1167–70.
| PubMed |
[15] Smith D, Berrey MM, Robertson M, Mehrotra D, Markowitz M, Perrin L, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182(3): 950–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[16] Capiluppi B, Ciuffreda D, Quinzan GP, Sciandra M, Marroni M, Morandini B, et al. Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters. J Biol Regul Homeost Agents 2000; 14(1): 58–62.
| PubMed |
[17] Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179(3): 527–37.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[18] Carcelain G, Blanc C, Leibowitch J, Mariot P, Mathez D, Schneider V, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999; 13(9): 1077–81.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[19] Lillo FB, Ciuffreda D, Veglia F, Capiluppi B, Mastrorilli E, Vergani B, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 1999; 13(7): 791–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[20] Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14(3): 243–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[21] Tamalet C, Pasquier C, Yahi N, Colson P, Poizot-Martin I, Lepeu G, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000; 61(2): 181–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[22] Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15(11): 1435–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[23] Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278(5342): 1447–50.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[24] Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97(7): 3382–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[25] Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193(2): 169–80.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[26] Zaunders JJ, Cunningham PH, Kelleher AD, Kaufman GR, Jaramillo AB, Wright R, et al. Potent antiretroviral therapy of primary human immunodefiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180 320–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[27] Dale CJ, Zhao A, Jones SL, Boyle DB, Ramshaw IA, Kent SJ. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma. J Med Primatol 2000; 29(3–4): 240–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[28] Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407(6803): 523–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[29] Girard PM, Schneider V, Dehee A, Mariot P, Jacomet C, Delphin N, et al. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS 2001; 15(2): 275–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[30] Lifson JD, Piatak M, Cline AN, Rossio JL, Purcell J, Pandrea I, et al. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 2003; 32(4–5): 201–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[31] Watson A, McClure J, Ranchalis J, Scheibel M, Schmidt A, Kennedy B, et al. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses 1997; 13(16): 1375–81.
| PubMed |
[32] Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to aids. J Infect Dis 2001; 183(10): 1466–75.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[33] Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16(15): 2049–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[34] Smith DE, Kaufmann GR, Kahn JO, Hecht FM, Grey PA, Zaunders JJ, et al. Greater reversal of CD4(+) cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003; 19(3): 189–99.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[35] Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333(7): 408–13.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[36] Lindback S, Vizzard J, Cooper DA, Gaines H. Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179(6): 1549–52.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[37] Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 1998; 178(1): 80–91.
| PubMed |
[38] Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340(21): 1683–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[39] Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186(5): 634–43.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[40] Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(7): F51–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[41] Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288(2): 207–15.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[42] Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185(1): 61–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
